Renata Soumarová

Prof. Dr. Renata Soumarová


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
RSRenata Soumarová
Renata Soumarová
LRL. Rušinová
L. Rušinová
Adjuvant radiotherapy after breast cancer surgery is an important part of breast cancer treatment improving local control and overall survival. However, a higher risk of cardiac mortality was observed when conventional radiotherapy techniques were used. Cardiac morbidity and mortality after radiation therapy have been studied in many meta-analyses. In those focused on modern radiotherapy techniques, cardiac morbidity and mortality were no longer presented. However, an extremely long follow-up period is required. Importantly, the cardiac morbidity rates vary depending not only on the dose delivered to the heart, but also on the systemic therapies administrated and the pre-existing cardiac disease. Systematic heart dose monitoring is of great importance, as are efforts to constantly decrease doses, using advanced radiotherapy techniques. Nowadays, it is essential to individualize treatment according to tumor characteristics and anatomical predispositions, and to consider the cost and benefits.

29 June 2021 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
TBTomáš Blažek
Tomáš Blažek
ZČZuzana Zděblová Čermáková
Zuzana Zděblová Čermáková
LKLukáš Knybel
Lukáš Knybel
PHPavel Hurník
Pavel Hurník
JSJan Stembirek
Jan Stembirek
RSRenata Soumarová
Renata Soumarová
Purpose: We evaluated the efficiency and toxicity of stereotactic hypofractionated boost in combination with conventionally fractionated radiotherapy in the treatment of advanced floor of the mouth cancer. Methods: Thirty-seven patients with advanced stage of the floor of the mouth cancer, histologically confirmed squamous cell carcinoma (p16 negative) ineligible for surgical treatment, were indicated for radiochemotherapy or hyperfractionated accelerated radiotherapy (HART). The radiotherapy protocol combined external beam radiotherapy (EBRT) and a stereotactic hypofractionated boost to the primary tumor. The dose delivered from EBRT was 70–72.5 Gy in 35/50 fractions. The hypofractionated boost followed with 10 Gy in two fractions. For the variables—tumor volume, stage and grade a multivariate analysis was performed to find the relationship between overall survival, local progression and metastasis. Toxicity was evaluated according to CTCAE scale version 4. Results: After a median follow-up of 16 months, 23 patients (62%) achieved complete remission. The median time to local progression and metastasis was 7 months. Local control (LC) at 2 and 5-years was 70% and 62%, respectively. Progression-free survival (PFS) and overall survival (OS) were 57% and 49% at 2 years and 41% and 27% at 5 years, respectively. Statistical analysis revealed that larger tumors had worse overall survival and a greater chance of metastasis. Log-Rank GTV > 44 ccm (HR = 1.96; [95% CI (0.87; 4.38)]; p = 0.11). No boost-related severe acute toxicity was observed. Late osteonecrosis was observed in 3 patients (8%). Conclusion: The combination of EBRT and stereotactic hypofractionated boost is safe and seems to be an effective option for dose escalation in patients with advanced floor of the mouth tumors who are ineligible for surgical treatment and require a non-invasive approach.

3 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MPMartin Palkovsky
Martin Palkovsky
NMNikol Modrackova
Nikol Modrackova
VNVera Neuzil-Bunesova
Vera Neuzil-Bunesova
MLMarian Liberko
Marian Liberko
AHAlzbeta Hlodakova
Alzbeta Hlodakova
RSRenata Soumarová
Renata Soumarová
Despite decades of research, cancer remains a major global health problem

1 January 2023 in Mathews Journal of Case Reports
Verified
Journal Article
Open access
PDF file
RSRenata Soumarová
Renata Soumarová
VMViktor Maňásek
Viktor Maňásek
IFIvan Ferák
Ivan Ferák
Favorable Long Term Outcome of Locally Advanced Adenocarcinoma Epididymis - An Extended Follow-Up: Case Report

15 October 2018 in Onkologie
Verified
Journal Article
Open access
PDF file
RSRenata Soumarová
Renata Soumarová
TBTomáš Blažek
Tomáš Blažek
Vysoce rizikové a lokálně pokročilé karcinomy prostaty zahrnují poměrně heterogenní skupinu onemocnění s různou prognózou

1 April 2018 in Onkologie
Verified
Journal Article
Open access
PDF file
RSRenata Soumarová
Renata Soumarová
Brachyterapie karcinomu prostaty patří mezi standardní léčebné metody lokalizovaného karcinomu prostaty společně s radikální prostatektomií a zevní radioterapií. Brachyterapie ve srovnání s ostatními metodami zevní radioterapie je nejlepší pro dodání vysoké dávky záření do prostaty a nejšetrnější k okolí. Pro svoji velmi nízkou morbiditu patří stále k velmi aktuálním a oblíbeným metodám léčby. Mezinárodní doporučení pro indikaci a optimální výběr pacientů jsou stále doplňována a